nnc0174-0833
Showing 1 - 7 of 7
Obesity, Overweight Trial in Overland Park (NNC0174-0833, Semaglutide, Placebo (NNC0174-0833))
Completed
- Obesity
- Overweight
- NNC0174-0833
- +2 more
-
Overland Park, KansasNovo Nordisk Investigational Site
Nov 16, 2021
Overweight, Obesity Trial in Montreal (NNC0174-0833, Oral contraceptive (OC) tablets, Acetaminophen)
Completed
- Overweight
- Obesity
- NNC0174-0833
- +2 more
-
Montreal, Quebec, CanadaNovo Nordisk Investigational Site
Jan 6, 2022
Overweight, Obesity Trial in Miami, Orlando (NNC0174-0833)
Completed
- Overweight
- Obesity
- NNC0174-0833
-
Miami, Florida
- +1 more
Jan 25, 2021
Overweight, Obesity Trial in Worldwide (NNC0174-0833, Placebo (NNC0174-0833), Liraglutide 3.0 mg)
Completed
- Overweight
- Obesity
- NNC0174-0833
- +3 more
-
Anaheim, California
- +53 more
Feb 24, 2022
Obesity, Overweight Trial in Glendale (NNC0174-0833, Placebo (NNC0174-0833))
Completed
- Obesity
- Overweight
- NNC0174-0833
- Placebo (NNC0174-0833)
-
Glendale, CaliforniaNovo Nordisk Investigational Site
Jun 21, 2019
Metabolism and Nutrition Disorder, Obesity Trial in Overland Park (NNC0174-0833, Placebo)
Completed
- Metabolism and Nutrition Disorder
- Obesity
- NNC0174-0833
- Placebo
-
Overland Park, KansasNovo Nordisk Investigational Site
Jan 31, 2018
Metabolism and Nutrition Disorder, Obesity Trial in Overland Park (NNC0174-0833, )
Completed
- Metabolism and Nutrition Disorder
- Obesity
- NNC0174-0833
- placebo
-
Overland Park, KansasNovo Nordisk Investigational Site
Jan 23, 2018